Cargando…

Van den Berghe's 5q- syndrome and myelodysplastic syndrome with isolated del(5q)

Detalles Bibliográficos
Autores principales:	Lima, Diego Silva, Costa, Paola Torres, Matos, Daniel Mazza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678786/ https://www.ncbi.nlm.nih.gov/pubmed/26670407 http://dx.doi.org/10.1016/j.bjhh.2015.08.001

Ejemplares similares

Van Den Bergh's Test in Jaundice
Publicado: (1925)

Further Studies on Van Den Bergh's Test
por: Chakravarti, Amulyaratan
Publicado: (1939)

Some Aspects of the Van den Bergh Test for Bilirubin
por: M'Gowan, J. P.
Publicado: (1929)

Frits van den Berghe, 1883-1939 : catalogue raisonné de son oeuvre peint.
por: Langui, Emile
Publicado: (1966)

The Alkali-Reserve of the Blood in Relation to the Van Den Bergh Bilirubin Test
por: M'Gowan, J. P.
Publicado: (1930)

Reply to van den Bergh and Savin: Fossil fuel taxes are politically hard to change
por: Martinez-Alvarez, Cesar B., et al.
Publicado: (2023)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q)
por: Invernizzi, Rosangela
Publicado: (2022)

Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment
por: Acha, Pamela, et al.
Publicado: (2022)

Del(5q) myelodysplastic syndrome combined with pure red cell aplasia
por: Park, Joowon
Publicado: (2018)

A Case of Near-triploidy in Myelodysplastic Syndrome with del(5q) Combined with del(1p) and del(13q)
por: Kim, Bo-Ram, et al.
Publicado: (2012)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report
por: Liang, Hai-Ping, et al.
Publicado: (2022)

Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
por: Acha, Pamela, et al.
Publicado: (2021)

Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q)
por: Zhang, Rui, et al.
Publicado: (2015)

5q Deletion Myelodysplastic Syndrome in a Young Male Patient
por: Elkattawy, Sherif, et al.
Publicado: (2021)

Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
por: Washington, Nyomi R, et al.
Publicado: (2021)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

MLL-SEPT5 Fusion Transcript in Myelodysplastic Syndrome Patient With t(11;22)(q23;q11)
por: Zou, Duobing, et al.
Publicado: (2021)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Part 4: Myelodysplastic syndromes—Treatment of low-risk patients with the 5q deletion
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018)

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
por: Feurstein, Simone, et al.
Publicado: (2018)

A case of myelodysplastic syndrome with t(10;18)(q26;q21)
por: Ohba, Yusuke, et al.
Publicado: (2019)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Part 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion
por: Velloso, Elvira Deolinda Rodrigues Pereira, et al.
Publicado: (2018)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
por: Scharenberg, Christian, et al.
Publicado: (2017)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
por: Hecht, Anna, et al.
Publicado: (2021)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Koh, Yu Han, et al.
Publicado: (2023)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1omoauj1ce46q71eg6k0j6445c